BioArctic AB
STO:BIOA B
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
139.9
277.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BIOA B stock under the Base Case scenario is 179.45 SEK. Compared to the current market price of 142.3 SEK, BioArctic AB is Undervalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
BioArctic AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BIOA B cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
BioArctic AB
Balance Sheet Decomposition
BioArctic AB
Current Assets | 1B |
Cash & Short-Term Investments | 489.7m |
Other Current Assets | 540.1m |
Non-Current Assets | 102.2m |
Long-Term Investments | 3.4m |
PP&E | 98.1m |
Other Non-Current Assets | 678k |
Current Liabilities | 143.5m |
Other Current Liabilities | 143.5m |
Non-Current Liabilities | 59.1m |
Long-Term Debt | 46.8m |
Other Non-Current Liabilities | 12.4m |
Earnings Waterfall
BioArctic AB
Revenue
|
299.3m
SEK
|
Cost of Revenue
|
-35.3m
SEK
|
Gross Profit
|
264.1m
SEK
|
Operating Expenses
|
-360.1m
SEK
|
Operating Income
|
-96m
SEK
|
Other Expenses
|
7.7m
SEK
|
Net Income
|
-88.3m
SEK
|
Free Cash Flow Analysis
BioArctic AB
SEK | |
Free Cash Flow | SEK |
BioArctic reported significant growth in Leqembi sales, particularly in the U.S. and Japan, with a strong launch in China. Leqembi is now approved in eight markets, representing over 80% of the expected global demand. The company anticipates a fivefold revenue increase, projecting sales to reach $2 billion by 2026. Net revenue for the quarter was SEK 50 million, with royalties projected to average SEK 120 million quarterly over the next year. Despite a negative EU decision, BioArctic is optimistic about a favorable reexamination and expects to be profitable next year. The company is advancing its portfolio, including a Phase IIa study for exidavnemab in Parkinson's disease.
What is Earnings Call?
BIOA B Profitability Score
Profitability Due Diligence
BioArctic AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
BioArctic AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
BIOA B Solvency Score
Solvency Due Diligence
BioArctic AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
BioArctic AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOA B Price Targets Summary
BioArctic AB
Dividends
Current shareholder yield for BIOA B is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BIOA B Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. The company is headquartered in Stockholm, Stockholm and currently employs 49 full-time employees. The company went IPO on 2017-10-12. The firm focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The firm owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The firm's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The firm also operates through SpineMedical AB.
Contact
IPO
Employees
Officers
The intrinsic value of one BIOA B stock under the Base Case scenario is 179.45 SEK.
Compared to the current market price of 142.3 SEK, BioArctic AB is Undervalued by 21%.